POLY-HF trial polypill success
Analysis based on 6 articles · First reported Jul 02, 2026 · Last updated Jul 21, 2026
The positive results of the POLY-HF trial could boost adoption of polypill formulations for heart failure, potentially increasing revenues for pharmaceutical companies that develop such combination products. Improved adherence and outcomes may reduce healthcare costs and hospitalizations, benefiting payers and patients.
The POLY-HF randomized clinical trial, led by University of Michigan Medicine and University of Texas Southwestern Medical Center, tested a once-daily polypill combining three guideline-recommended heart failure medications (metoprolol succinate, spironolactone, empagliflozin) plus a separate renin-angiotensin system inhibitor in 212 patients with heart failure with reduced ejection fraction (HFrEF). After six months, the polypill group showed a 3.3 percentage point greater improvement in left ventricular ejection fraction, a 60% lower rate of heart failure-related hospitalizations or emergency visits, and significantly higher medication adherence (79% vs 54%) compared to the group taking separate pills. The findings were published in Nature Medicine and funded by the United States — National Institutes of Health. The study suggests that simplifying complex drug regimens into a single pill could improve outcomes for heart failure patients and potentially for other conditions requiring multidrug therapy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard